arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

RECURSION PHARMACEUTICALS, INC.

RXRX

$3.71 ▼ -0.34 (-8.40%) at close

8 Visible periods

29 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

RECURSION PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.7B

Dividend Yield —

Revenue Growth 26.9% ↘

Op. Margin —

ROIC -57.3% ↘

FCF / Share $-0.85 ↗

Trailing P/E —

Price / Book 1.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$74.68M

↑ +26.9% —

Net Income Profit after all expenses

$-644.76M

↓ -39.1% —

FCF / Share Free cash flow per share

$-0.85

↑ +37.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	26.9% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+237%)	32.0% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+300%)	11.9% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+48%)	291.5% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3543%)	156.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1861%)	70.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+786%)	—	—
EPS Growth YoY (%)	14.8% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-7.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-16.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	8.7% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	62.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-39.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-39.1% Weak ↓ Weak Declining Year-over-year change in net income	-41.3% Weak ↑ Weak Improving Year-over-year change in net income	-37.0% Weak ↑ Weak Improving Year-over-year change in net income	-28.4% Weak ↑ Weak Improving Year-over-year change in net income	-114.3% Weak Weak Year-over-year change in net income	-40.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	37.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	5.7% Fair ↑ Fair Improving Year-over-year change in free cash flow	-109.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	56.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	32.7% Excellent Excellent Year-over-year change in free cash flow	16.8% Good Good Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	23.3% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	79.5% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	124.1% Excellent Excellent Compound annual revenue growth over 3 years	158.0% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	79.9% Excellent Excellent Compound annual revenue growth over 5 years	90.9% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
FCF Margin (%) (%)	—	—	—	-302.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.50x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-57.3% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-46.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-74.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-50.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	32.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	39.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-44.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-33.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-53.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-35.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-29.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-28.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-57.0% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-480%)	-44.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-399%)	-70.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-572%)	-49.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-429%)	-34.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-329%)	42.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+181%)	49.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+232%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Debt to Equity (x)	—	—	—	—	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—
Interest Coverage (x)	—	—	-3608.87x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-4467.76x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-61.92x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-62.22x Weak Weak Operating income divided by interest expense Optimal: > 5x	-98.33x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-743.29M	$-594.35M	$-391.56M	$-549.91M	$-284.39M	$-262.13M	—	—
Debt / EBITDA (x)	—	—	—	—	-0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.17	$0.21	$0.21	$0.23	$0.08	$0.18	$0.11	—
Basic EPS, GAAP (USD)	$-1.44	$-1.69	$-1.58	$-1.36	$-1.49	$-3.99	$-2.87	—
Free Cash Flow per Share (USD)	$-0.85	$-1.36	$-1.44	$-0.69	$-1.58	$-2.35	$-2.83	—
Book Value per Share (USD)	$2.14	$2.61	$1.98	$2.54	$3.19	$-9.24	$-5.76	—
Tangible Book Value per Share (USD)	$1.25	$1.39	$1.60	$2.53	$3.18	$-9.36	$-5.76	—
Basic Weighted Avg Shares (shares)	447.45M	274.21M	207.85M	175.54M	125.35M	21.78M	21.57M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$665.14M	$526.80M	$344.97M	$469.55M	$488.06M	$243.34M	—	—
LT Debt (USD)	—	—	—	—	$723.00K	—	—	—
Total Equity (USD)	$1.13B	$1.03B	$463.44M	$485.81M	$542.94M	$-206.29M	$-124.27M	$-63.85M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$74.68M	$58.84M	$44.58M	$39.84M	$10.18M	$3.96M	$2.32M	—
Depreciation Expense (USD)	$83.70M	$36.49M	$24.40M	$11.76M	$8.40M	$3.94M	$2.49M	—
Net Income, GAAP (USD)	$-644.76M	$-463.66M	$-328.07M	$-239.48M	$-186.48M	$-87.01M	$-61.88M	—
Operating Cash Flow (USD)	$-371.81M	$-359.17M	$-287.78M	$-83.52M	$-158.61M	$-45.40M	$-57.04M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 28 quarters

RECURSION PHARMACEUTICALS, INC.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RXRX with peers